Savient Pharmaceuticals (SVNT -0.5%) gives back earlier gains after the results from two Phase...

|About: Savient Pharmaceuticals, Inc. (SVNTQ)|By:, SA News Editor

Savient Pharmaceuticals (SVNT -0.5%) gives back earlier gains after the results from two Phase III studies of its drug Krystexxa showed significant reductions in uric acid levels among a substantial number of patients with refractory chronic gout.